Connect with us


Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency – Yahoo Finance

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that in a Phase 2 proof-of-concept study, VX-864 achieved…



Article feature image

– Treatment with VX-864 led to a statistically significant increase from baseline in plasma functional AAT levels as compared to placebo and was generally well tolerated –
– Results provide proof-of-mechanism, although magnitude of treatment effect observed…

Click here to view the original article.

Continue Reading

You might also like ...

Article feature image
How bad are global shipping snafus? Home Depot contracted its own container ship as a safeguard – CNBC
Article feature image
Delta flight diverted after off-duty flight attendant becomes unruly – CBS News
Article feature image
These 3 Internet of Things Companies Have Incredibly Wide Moats – Motley Fool